The company's innovative multiple cell (NK, DC, car-t, CTL, etc.) related technologies for cancer treatment have been very mature, and clinical experimental research is in progress.
In cooperation with NCI, the company has developed the third generation of CD19 car-t and CD20 car-t, which can be used in the treatment of acute and chronic B-cell lymphoid leukemia and lymphoma. At present, the fourth generation car-t is being developed with the goal of increasing its safety through structural modification of car-t.
Under the technical guidance of Professor Xu Conggao (innovative talents from Haiyou of high tech Zone), the company is cooperating with Shandong cancer hospital to carry out clinical treatment of tumors (modified DC-CIK cells for tumor treatment; Til for solid tumors, malignant pleural effusion and ascites; DCS vaccine loaded with anti-tumor specific antigen in peripheral blood and sequential therapy of anti-tumor specific T cells; TCR The research on anti-tumor specificity is mature), and strive to make the company take the lead in the research and development of individual cell immunotherapy tumor.
